Scholars Central

Conference abstractPublished 19 Sep 2018

Pin1-catalyzed conformational regulation as a common oncogenic signaling mechanism and a unique drug target

Authors: Xiao Zhen Zhou

Harvard Medical School, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

It has become evident that the activation of multiple interactive/redundant oncogenic pathways and the presence of cancer stem cells are two major sources of drug resistance in modern cancer therapy. Pin1 is a unique phosphorylation-specific proline isomerase that functions as a master regulator of oncogenic signaling networks. It simultaneously activates at least 43 oncoproteins and inactivates over 20 tumor suppressors and global miRNAs to activate multiple oncogenic pathways and expand cancer stem cells in various cancers. However, Pin1 inhibitors are lacking. Our recent mechanism-based high throughput screens have led to the unexpected discovery that all-trans retinoic acid (ATRA) is a Pin1 inhibitor. The combination of ATRA with arsenic trioxide (ATO) has transformed acute promyelocytic leukemia (APL) from being highly fatal to highly curable, but their mechanisms of action and efficacy aren’t fully understood. We have shown that ATRA inhibits APL, acute myeloid leukemia, breast and liver cancer by directly binds to and induces Pin1 degradation. We have further shown that ATO also inhibits and degrades Pin1, and suppresses its oncogenic function by noncovalent binding to Pin1â??s active site. ATO’s anticancer activity is potentiated by ATRA, which increases cellular ATO uptake through upregulating aquaporin-9. ATO and ATRA, at clinically safe doses, cooperatively ablate Pin1 to block numerous. Cancer-driving pathways and inhibit the growth of triplenegative breast cancer cells and cancer stem cells in cell and animal models including patient-derived orthotopic xenografts, like Pin1 knockout, which is substantiated by comprehensive protein and microRNA analyses. These results not only identify Pin1 as the elusive drug target for ATO and ATRA, but also establish a proof-of-concept that targeting of Pin1 by ATO and ATRA or other more potent and specific Pin1 inhibitors offers an attractive approach to combating breast and many other cancers.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cell Signaling.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Signaling
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Xiao Zhen Zhou”